BCDA Insider Trading

Insider Ownership Percentage: 20.00%
Insider Buying (Last 12 Months): $59,215.00
Insider Selling (Last 12 Months): $55,811.85

BioCardia Insider Trading History Chart

This chart shows the insider buying and selling history at BioCardia by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

BioCardia Share Price & Price History

Current Price: $2.91
Price Change: Price Decrease of -0.04 (-1.36%)
As of 07/19/2024 01:00 AM ET

This chart shows the closing price history over time for BCDA up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

BioCardia Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/1/2024Peter AltmanCEOBuy300$3.05$915.0039,745View SEC Filing Icon  
6/28/2024Peter AltmanCEOBuy200$2.99$598.0039,445View SEC Filing Icon  
6/21/2024Peter AltmanCEOBuy500$3.29$1,645.0039,245View SEC Filing Icon  
6/14/2024Peter AltmanCEOBuy500$3.52$1,760.0038,745View SEC Filing Icon  
6/10/2024Peter AltmanCEOBuy1,000$3.36$3,360.0038,245View SEC Filing Icon  
4/19/2024Peter AltmanCEOBuy183$5.55$1,015.6537,246View SEC Filing Icon  
3/28/2024Peter AltmanCEOBuy33$5.85$193.0537,063View SEC Filing Icon  
2/13/2024Peter AltmanCEOBuy7,207$6.90$49,728.3037,029View SEC Filing Icon  
1/19/2024Phillip Md Et Al FrostMajor ShareholderSell8,653$6.45$55,811.85126,401View SEC Filing Icon  
5/26/2023Peter AltmanCEOBuy413$24.00$9,912.0031,282View SEC Filing Icon  
1/11/2023Peter AltmanCEOBuy6$28.05$168.3023,581View SEC Filing Icon  
12/16/2022Phillip Md Et Al FrostMajor ShareholderBuy39,682$25.20$999,986.40135,055View SEC Filing Icon  
10/10/2022David McclungCFOBuy133$31.05$4,129.655,234View SEC Filing Icon  
9/23/2022Peter AltmanCEOBuy93$28.05$2,608.6521,896View SEC Filing Icon  
9/21/2022Peter AltmanCEOBuy183$28.80$5,270.4021,596View SEC Filing Icon  
6/10/2022Peter AltmanCEOBuy300$21.90$6,570.0021,413View SEC Filing Icon  
5/13/2022Peter AltmanCEOBuy179$20.70$3,705.3023,209View SEC Filing Icon  
5/11/2022Peter AltmanCEOBuy66$19.50$1,287.0022,276View SEC Filing Icon  
4/28/2022Peter AltmanCEOBuy153$23.85$3,649.0522,029View SEC Filing Icon  
4/18/2022Peter AltmanCEOBuy900$20.85$18,765.0021,876View SEC Filing Icon  
11/18/2021Peter AltmanCEOBuy333$33.00$10,989.00View SEC Filing Icon  
8/17/2021Peter AltmanCEOBuy233$44.10$10,275.3015,527View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for BioCardia (NASDAQ:BCDA)

20.57% of BioCardia stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at BCDA by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

BioCardia Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
11/7/2023CM Management LLC600,000$0.26M0.3%+74.9%2.775%Search for SEC Filing on Google Icon
8/4/2023CM Management LLC343,000$0.92M0.9%+4.3%1.677%Search for SEC Filing on Google Icon
7/24/2023Vontobel Holding Ltd.30,751$82K0.0%+93.5%0.150%Search for SEC Filing on Google Icon
5/15/2023AIGH Capital Management LLC509,151$0.99M0.4%-14.5%2.523%Search for SEC Filing on Google Icon
4/12/2023Vontobel Holding Ltd.15,895$31K0.0%N/A0.079%Search for SEC Filing on Google Icon
2/16/2023AIGH Capital Management LLC595,237$1.24M0.4%N/A2.969%Search for SEC Filing on Google Icon
11/15/2022Family Management Corp142,186$0.28M0.1%N/A0.797%Search for SEC Filing on Google Icon
5/4/2022Commonwealth Equity Services LLC49,978$0.10M0.0%+18.1%0.296%Search for SEC Filing on Google Icon
1/31/2022Commonwealth Equity Services LLC42,307$82K0.0%+156.5%0.251%Search for SEC Filing on Google Icon
11/5/2021Advisor Group Holdings Inc.39,257$0.12M0.0%-8.4%0.233%Search for SEC Filing on Google Icon
10/29/2021Commonwealth Equity Services LLC16,492$51K0.0%N/A0.098%Search for SEC Filing on Google Icon
9/17/2021Virtu Financial LLC33,264$0.13M0.0%N/A0.197%Search for SEC Filing on Google Icon
8/25/2021Marshall Wace LLP21,680$86K0.0%-45.7%0.129%Search for SEC Filing on Google Icon
8/16/2021Marshall Wace LLP21,680$86K0.0%-45.7%0.129%Search for SEC Filing on Google Icon
8/13/2021Renaissance Technologies LLC102,230$0.41M0.0%-66.5%0.609%Search for SEC Filing on Google Icon
8/13/2021Geode Capital Management LLC76,825$0.30M0.0%+23.6%0.457%Search for SEC Filing on Google Icon
8/13/2021Vanguard Group Inc.411,969$1.64M0.0%+67.8%2.453%Search for SEC Filing on Google Icon
8/10/2021CM Management LLC329,000$1.31M0.9%+5.1%1.959%Search for SEC Filing on Google Icon
8/6/2021Magnus Financial Group LLC15,000$60K0.0%N/A0.089%Search for SEC Filing on Google Icon
5/19/2021Squarepoint Ops LLC46,945$0.20M0.0%N/A0.280%Search for SEC Filing on Google Icon
5/13/2021Renaissance Technologies LLC305,200$1.33M0.0%N/A1.817%Search for SEC Filing on Google Icon
5/12/2021Geode Capital Management LLC62,168$0.27M0.0%+175.6%0.370%Search for SEC Filing on Google Icon
5/12/2021CM Management LLC313,100$1.36M1.0%+36.1%1.864%Search for SEC Filing on Google Icon
2/9/2021Bank of New York Mellon Corp16,294$56K0.0%N/A0.131%Search for SEC Filing on Google Icon
2/5/2021CM Management LLC230,000$0.80M0.7%N/A1.851%Search for SEC Filing on Google Icon
8/17/2020Jane Street Group LLC14,688$35K0.0%N/A0.214%Search for SEC Filing on Google Icon
8/14/2020Captrust Financial Advisors659,179$1.62M0.0%N/A9.626%Search for SEC Filing on Google Icon
8/14/2020Advisor Group Holdings Inc.85,002$0.20M0.0%-7.7%1.241%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
BioCardia logo
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its leading product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. BioCardia, Inc. is based in Sunnyvale, California.
Read More on BioCardia

Today's Range

Now: $2.91
Low: $2.86
High: $3.00

50 Day Range

MA: $3.96
Low: $2.83
High: $6.09

52 Week Range

Now: $2.91
Low: $2.62
High: $35.40

Volume

7,927 shs

Average Volume

84,888 shs

Market Capitalization

$5.30 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.37

Who are the company insiders with the largest holdings of BioCardia?

BioCardia's top insider investors include:
  1. Phillip Md Et Al Frost (Major Shareholder)
  2. Peter Altman (CEO)
  3. David Mcclung (CFO)
Learn More about top insider investors at BioCardia.